Most Read Articles
20 May 2019

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.
Jairia Dela Cruz, 10 Jun 2019
Statins appear to exert neuroprotective effects in diabetic prostate cancer patients receiving androgen deprivation therapy (ADT), with a recent study showing that the drug confers benefit for the risk of dementia. The benefit is greater with higher statin adherence and intensity.

Topical 5-fluorouracil, interferon alfa-2b eye drops both effective, safe for OSSN

15 Dec 2018

Topical 5-fluorouracil 1% (5FU) is as good as interferon alfa-2b 1 MIU/mL (IFN) eye drops in the primary treatment of ocular surface squamous neoplasia (OSSN), with both modalities leading to high tumour resolution and low recurrence rates, a recent study has shown.

Researchers examined the medical records of 54 patients who received 5FU and 48 patients who received IFN as primary therapy for OSSN. Primary outcome measures included the frequency of clinical resolution and time to OSSN recurrence. Secondary outcome was the frequency of side effects with each therapy.

The mean age of the cohort was 68 years, and a greater proportion of Hispanics were treated with 5FU. In a univariable analysis, the frequency of OSSN resolution was higher with 5FU than with IFN (96.3 percent vs 81.3 percent; p=0.01). However, multivariable analysis showed that treatment modality was not a significant predictor of resolution.

Among patients with resolved OSSN, mean time to resolution was similar between 5FU and IFN (mean 6.6 vs 5.5 months; p=0.17). Likewise, there was no significant difference in the number of resolved lesions that recurred (6 of 52 eyes vs 2 of 39 eyes, respectively; p=0.46), with Kaplan Meier survival curves of OSSN recurrence being similar between the two teatment groups (log rank=0.16).

Recurrence rates at 1 year were 11.4 percent with 5FU and 4.5 percent with IFN. Adverse events such as eyelid oedema (p=0.04) and tearing (p=0.02) were more significant with 5FU.

The present data suggest that both topical 5FU and IFN eye drops are effective treatment options for OSSN.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
20 May 2019

Dr Michael Lim, a senior consultant at the Paediatric Pulmonary and Sleep Division, National University Hospital, Singapore, speaks to Roshini Claire Anthony on the rare disease that is cystic fibrosis.

31 May 2019
Co-therapy with proton pump inhibitors (PPIs) in patients receiving low-dose anticoagulation and/or aspirin for stable cardiovascular disease confers no benefit for upper gastrointestinal events but may reduce bleeding due to gastroduodenal lesions, a study has shown.
Laura Kho Sui San , 29 May 2019
Anxiety becomes a pathological disorder when it occurs for no detectable reason, persists and interferes with daily activities like work performance and relationships.
Jairia Dela Cruz, 10 Jun 2019
Statins appear to exert neuroprotective effects in diabetic prostate cancer patients receiving androgen deprivation therapy (ADT), with a recent study showing that the drug confers benefit for the risk of dementia. The benefit is greater with higher statin adherence and intensity.